exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087782 RNA Name: hsa-miR-146a-5p RNA Type: miRNA Chromosome: chr5 Starnd: + Coordinate: Start Site(bp): 160485372 End Site(bp): 160485393 External Links: hsa-miR-146a-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ALDOA chr16 30064164 30070457 + ATP6V0D1 chr16 67438014 67481181 - FXYD3 chr19 35115879 35124324 + GATAD1 chr7 92447482 92460075 + HYOU1 chr11 119044188 119057227 - JPT2 chr16 1678256 1702280 + NFIX chr19 12995608 13098796 + RNF169 chr11 74748849 74842413 + SKA2 chr17 59109857 59155260 - SS18 chr18 26016253 26091217 - TACC1 chr8 38728186 38853028 + WDR45B chr17 82614562 82648553 - ZNF512B chr20 63956704 63969930 - ZNRF3 chr22 28883572 29057488 + APEH chr3 49674014 49683971 + DCAF1 chr3 51395867 51500002 - GNAS chr20 58839718 58911192 + HSP90AA1 chr14 102080738 102139699 - KDM1A chr1 23019443 23083689 + MARCKS chr6 113857345 113863475 + NDUFS2 chr1 161197104 161214395 + RBBP7 chrX 16839283 16870414 - RPL9 chr4 39452521 39458949 - SAP18 chr13 21140514 21149084 + SLC25A5 chrX 119468422 119471396 + SPAG5 chr17 28577565 28599025 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000418 chr12 69983264 69985939 + hsa_circ_0001361 chr3 171830241 171851336 + hsa_circ_0000943 chr19 47421744 47440665 + hsa_circ_0000799 chr17 65941524 65972074 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand KCNQ1OT1 chr11 2608328 2699994 - MALAT1 chr11 65497688 65506516 + NEAT1 chr11 65422774 65445540 + SNHG16 chr17 76557764 76565348 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.